Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study

Table 2 Patient disposition, Re-treatment and reasons for discontinuation

Parameter	Group 1 (1 × 6 mL)	Group 2 (1 × 4 mL)	Group 3 (2 × 4 mL)	Group 4 (3 × 4 mL)	Group 5 (3 × 2 mL)	Overall N (%)
Number of patients enrolled	20	21	19	20	20	100
Randomised	20	21	20	20	21	100 (100)
Completed study	20	20	19	20	19	98 (98)
Discontinued study	0	1	1	0	2	4 (4)
Adverse event	0	0	0	0	1	1 (1)
Wished to withdraw	0	0	1	0	0	1 (1)
Lack of efficacy	0	1	0	0	0	1 (1)
Other	0	0	0	0	1	1 (1)
Re-treated
Number of patients enrolled	3	4	7	5	5	24
Completed study	3	4	7	4	5	23 (95.8)
Discontinued study	0	0	0	1	0	1 (4.2)
Adverse event	0	0	0	1	0	1 (4.2)
Not re-treated
Number of patients enrolled	12	9	10	12	11	54
Completed study	12	9	9	12	10	52 (96.3)
Discontinued study	0	0	1	0	1	2 (3.7)
Lost to follow-up	0	0	1	0	1	2 (3.7)